SKAN Group AG
SIX:SKAN

Watchlist Manager
SKAN Group AG Logo
SKAN Group AG
SIX:SKAN
Watchlist
Price: 46.85 CHF -1.78% Market Closed
Market Cap: CHf1.1B

SKAN Group AG
Accrued Liabilities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

SKAN Group AG
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
SKAN Group AG
SIX:SKAN
Accrued Liabilities
CHf15.6m
CAGR 3-Years
42%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bachem Holding AG
SIX:BANB
Accrued Liabilities
CHf47.9m
CAGR 3-Years
8%
CAGR 5-Years
12%
CAGR 10-Years
15%
Siegfried Holding AG
SIX:SFZN
Accrued Liabilities
CHf63.5m
CAGR 3-Years
7%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Lonza Group AG
SIX:LONN
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Tecan Group AG
SIX:TECN
Accrued Liabilities
CHf97.3m
CAGR 3-Years
-4%
CAGR 5-Years
5%
CAGR 10-Years
N/A
PolyPeptide Group AG
SIX:PPGN
Accrued Liabilities
€16.2m
CAGR 3-Years
9%
CAGR 5-Years
4%
CAGR 10-Years
N/A
No Stocks Found

SKAN Group AG
Glance View

SKAN Group AG, headquartered in Switzerland, has carved out its niche as a leading innovator in the realm of contamination control for aseptic environments. The company's history traces back to its founding in 1968, following the rapid advancements in the pharmaceutical and biotechnology sectors. SKAN has since developed a sterling reputation for its pioneering work in isolator technology, offering solutions that ensure the highest standards of sterility and safety critical to these industries. The company designs and manufactures isolators, which are essentially sealed environments that provide contamination-free zones for the processing of materials or production of pharmaceuticals, ensuring that even the most sensitive products are handled with stringent safety measures. This focus on high-tech, specialized equipment forms the backbone of SKAN's revenue model. By providing bespoke solutions tailored to the unique requirements of its clients, SKAN taps into the lucrative markets of pharmaceutical production and research, biotechnology companies, and laboratories that demand high-performance contamination barriers. Beyond just the sale of equipment, SKAN also offers a comprehensive suite of services, including installation, validation, maintenance, and training, ensuring a steady flow of income as these businesses need continual updates and technical support for their critical infrastructure. The demand for stricter health regulations and more advanced pharmaceuticals continues to rise, positioning SKAN Group AG as a pivotal player in this essential industry, capitalizing on its expertise to ensure both safety and compliance for its customers worldwide.

SKAN Intrinsic Value
68.31 CHF
Undervaluation 31%
Intrinsic Value
Price CHf46.85

See Also

What is SKAN Group AG's Accrued Liabilities?
Accrued Liabilities
15.6m CHF

Based on the financial report for Dec 31, 2025, SKAN Group AG's Accrued Liabilities amounts to 15.6m CHF.

What is SKAN Group AG's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 3Y
42%

Over the last year, the Accrued Liabilities growth was 154%. The average annual Accrued Liabilities growth rates for SKAN Group AG have been 42% over the past three years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett